

AUTHORIZED USERS INFORMATION

Your company is a Subscriber to the Drug Interaction Database (DIDB).

This information outlines conditions on use of the DIDB.

Authorized Users:

- Only authorized users may access and use the DIDB and no access can granted for any third party purpose.
- Authorized Users are defined in the License as: "Authorized User" are current employees or students of the Subscriber, who are permitted to access the Work from within the Subscriber's premises or from such other places where Authorized Users occasionally perform their work for the Subscriber, who are conducting work for only the Subscriber's benefit, have been notified of the disclaimers in the Agreement, and who have been given a password by Subscriber.

Use:

- Users may display, query, and view results from DIDB.
- User may not sublicense, sell, publicly display, lend, rent, lease or otherwise transfer all or any of DIDB.

Downloading:

- As an Authorized User, you may download portions of the DIDB.
- You may save individual articles displayed in the DIDB format on your desktop for temporary use. You shall remove such portions of the DIDB and/or articles displayed in the DIDB format as soon as practicable.
- You shall not share the DIDB with anyone other than other Authorized Users in your company. You may not send downloaded or printed portions of the DIDB to external contacts, clients or other persons who are not Authorized Users.
- You may not download the entire DIDB or substantial portions of the DIDB for any purpose, including local storage or use.

Printing:

- You may print output from the DIDB provided the printouts are for internal use and do not constitute a substantial portion of the DIDB.

Intellectual Property and Copyright:

- The DIDB is the intellectual property of the University of Washington. Copyright in the database is by the University of Washington and should be cited as follows: Copyright University of Washington 1999-2006. Metabolism and Transport Drug Interaction Database. Accessed: [Fill in appropriate information]... "
- In licensing the DIDB, your company does not acquire any proprietary interest in the DIDB.
- You may not remove or obscure rights management markings, such as copyright notices and patent numbers, from the DIDB or from any printout from the DIDB.

Disclaimers:

The DIDB has been developed as part of research conducted at the University of Washington. The DIDB is experimental in nature and is made available “AS IS,” without obligation by UW to provide accompanying services or support except as specified in this Agreement. The entire risk as to the quality and performance of the DIDB is with Subscriber.

Subscriber acknowledges that the intended audience for the DIDB is researchers knowledgeable in drug interaction, and that no clinical use of the DIDB is intended or allowed by this Agreement. Subscriber acknowledges that the DIDB is solely a selected compilation of publicly available literature, and UW makes no warranty on the accuracy, validity, completeness or availability of information cited in the DIDB. The information contained in the DIDB is intended as a supplement to, and not a substitute for, the knowledge, expertise, skill and judgment of Authorized Users. The absence of a warning for a given drug or drug combination should not be construed to indicate that the drug or drug combination is safe, appropriate or effective in any given patient.

Contact for Questions and Information on the Subscription Agreement:

The Drug Interaction Database (DIDB) is made available through a Subscription Agreement between your company and the University of Washington and use of the DIDB is defined by the terms and conditions of the Subscription Agreement.

For Technical Information on the DIDB: Contact didbase@u.washington.edu